The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)
Publications
Safety of infliximab in Crohn's disease: a large single-center experience.
Inflammatory bowel diseases 2010 Dec;16;2109-16 — 2010 Dec — 2109-16
Are biologics safe in the treatment of atopic dermatitis? A review with a focus on immediate hypersensitivity reactions.
Journal of the American Academy of Dermatology 2009 Oct;61;666-76 — 2009 Oct — 666-76
Correlation between atopy and hypersensitivity reactions during therapy with three different TNF-alpha blocking agents in rheumatoid arthritis.
Clinical and experimental rheumatology 2009 Mar-Apr;27;333-6 — 2009 Mar-Apr — 333-6
Clinical immunotoxicity of therapeutic proteins.
Expert opinion on drug metabolism & toxicology 2008 Dec;4;1537-49 — 2008 Dec — 1537-49
The incidence and management of infusion reactions to infliximab: a large center experience.
The American journal of gastroenterology 2003 Jun;98;1315-24 — 2003 Jun — 1315-24